{"nctId":"NCT01049373","briefTitle":"Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain","startDateStruct":{"date":"2003-12"},"conditions":["Low Back Pain"],"count":221,"armGroups":[{"label":"Lymphdiaral Basistropfen (HDC)","type":"EXPERIMENTAL","interventionNames":["Drug: HDC"]},{"label":"Placebo Solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo solution"]}],"interventions":[{"name":"HDC","otherNames":["Lymphdiaral Basistropfen"]},{"name":"Placebo solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female patients\n* Aged 18 - 75 years\n* Chronic low-back pain lasting at least for 6 months\n* Hanover functional ability questionnaire (FFbH-R) score less than 70%\n* At least one of the following diagnoses:\n\n  1. Chronic lumbar ischialgia with or without radicular radiation\n  2. Chronic degenerative lumbar syndrome\n  3. Spondylarthrosis\n  4. Chronic facet syndrome\n  5. Lumbago with protrusion of the intervertebral disc\n  6. Lumbar radiculopathy\n  7. Lumbar and other intervertebral disc impairments with radiculopathy\n  8. Back pain at different locations of the spine\n* Written, informed consent\n\nExclusion Criteria:\n\n* Participation in another clinical trial/GCP-trial within 30 days prior to screening\n* Participation in this trial in an earlier time\n* Treatment with lymphdiaral basistropfen within 3 month prior to enrolment\n* Pregnancy and lactation\n* Non-compliance\n* Incapability to understand the sense of the study\n* Abuse of analgesics, opiates or other drugs\n* Chronic pain that are as strong as or even stronger than the pain caused by the low-back and that need to be treated with analgesics\n* Malign diseases\n* Pathological neurological states\n* Epilepsy\n* Operation of the spine within 3 month prior to enrolment\n* Fractures of the spine\n* Bechterew's disease\n* Alcohol abuse\n* Consuming diseases\n* Cachexia\n* Palsy of the legs or anal sphincter due to acute impairment of the intervertebral disc\n* Catheterisation or CT-controlled intra-articular injection in the lumbar region\n* Hypersensitivity against one of the ingredients or excipients of the study drugs or against composite plants in general\n* Systemic, progressive diseases like tuberculosis, leucosis, collagenosis, multiple sclerosis, acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, or other auto-immune diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in FFbH-R Between Screening and Week 15","description":"Hannover Functional Questionnaire (FFbH-R) As used in this study test FFbH-R is a special version of the FFbH \"for close to everyday diagnostics of functional impairment by back pain\". It is a patient questionnaire, which consists of 12 questions for the acquisition of functional limitations consists in activities of daily living.\n\nChange in FFbH-R between screening and week 15 Scale ranges from 0 (=worst) to 100(=best)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"15.0"},{"groupId":"OG001","value":"4.1","spread":"15.3"}]}]}]},{"type":"SECONDARY","title":"Change in FFbH-R Between Screening and 2 Weeks","description":"Hannover Functional Questionnaire (FFbH-R) As used in this study test FFbH-R is a special version of the FFbH \"for close to everyday diagnostics of functional impairment by back pain\". It is a patient questionnaire, which consists of 12 questions for the acquisition of functional limitations consists in activities of daily living.\n\nChange in FFbH-R between screening and 2 weeks Scale ranges from 0 (=worst) to 100(=best)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"12.8"},{"groupId":"OG001","value":"0.6","spread":"12.7"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Score (SES), Subscale \"Sensoric Pain\"","description":"Pain Perception Scale (SES) The SES is a patient questionnaire, which consists of 24 questions, both the affective (14 questions) and sensoric (10 questions) depict aspects.\n\nDifference between V1 minus V-1 in the subscale \"sensoric pain\" Scale ranges from 10(=best) to 40(=worst)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"7.5"},{"groupId":"OG001","value":"-1.8","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Change in Pain Score (SES), Subscale \"Sensoric Pain\"","description":"Pain Perception Scale (SES) The SES is a patient questionnaire, which consists of 24 questions, both the affective (14 questions) and sensoric (10 questions) depict aspects.\n\nDifference between screening and 15 weeks in the subscale \"sensoric pain\" Scale ranges from 10(=best) to 40(=worst)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"6.8"},{"groupId":"OG001","value":"-3.9","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Change in Strength of Pain (Visual Analog Scale VAS)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Strength of Pain (Visual Analog Scale VAS)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in State of Health (BF-S)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in State of Health (BF-S)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Oswestry Score","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Oswestry Score","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Short Form Health Survey 12 Items (SF-12)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change in Short Form Health Survey 12 Items (SF-12) Ment","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Correlation of Efficacy With the Constitutional Type of the Patient, Measured by the Hattinger Constitutional Manual (HKM) and the Hattinger Constitutional Questionnaire (HKF)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Amount of Analgesics Used","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Days With Incapability to Work","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of ADRs","description":"frequency of ADR with a probable or possible causal relationship","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":112},"commonTop":["Headache","Pruritus","Dizziness","Nasopharyngitis","Arthralgia"]}}}